CRIS Current Research Information System

GRAMANTIERI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.370
EU - Europa 1.760
AS - Asia 804
AF - Africa 103
Continente sconosciuto - Info sul continente non disponibili 16
SA - Sud America 11
Totale 5.064
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.361
IT - Italia 415
GB - Regno Unito 377
CN - Cina 299
SG - Singapore 278
SE - Svezia 251
DE - Germania 194
IN - India 106
IE - Irlanda 86
CH - Svizzera 77
RU - Federazione Russa 77
FR - Francia 63
UA - Ucraina 58
VN - Vietnam 48
BG - Bulgaria 41
TG - Togo 40
ZA - Sudafrica 32
FI - Finlandia 29
EE - Estonia 28
ID - Indonesia 23
JO - Giordania 21
EU - Europa 15
CI - Costa d'Avorio 13
NL - Olanda 11
BE - Belgio 9
HR - Croazia 9
MK - Macedonia 9
CA - Canada 8
EC - Ecuador 8
NG - Nigeria 6
IL - Israele 5
PL - Polonia 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
RO - Romania 4
SC - Seychelles 4
AM - Armenia 3
GR - Grecia 3
LB - Libano 3
PK - Pakistan 3
AT - Austria 2
BR - Brasile 2
DK - Danimarca 2
ES - Italia 2
HK - Hong Kong 2
JP - Giappone 2
KZ - Kazakistan 2
MD - Moldavia 2
SI - Slovenia 2
TN - Tunisia 2
TR - Turchia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
CU - Cuba 1
EG - Egitto 1
IR - Iran 1
KE - Kenya 1
KR - Corea 1
LK - Sri Lanka 1
MY - Malesia 1
PE - Perù 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 5.064
Salva come PNG Salva come JPEG
Città #
Southend 349
Fairfield 302
Singapore 238
Chandler 214
Ashburn 190
Woodbridge 159
Santa Clara 150
Houston 141
Wilmington 129
Seattle 126
Bologna 125
Princeton 88
Dublin 86
Ann Arbor 79
Cambridge 79
Bern 75
Boardman 72
Sofia 41
Lomé 40
Dong Ket 35
Jacksonville 34
Westminster 34
Padova 32
Nanjing 31
Helsinki 26
Beijing 23
Berlin 23
Amman 21
Jakarta 21
Milan 20
Saint Petersburg 19
Jinan 18
New York 18
Hebei 17
San Diego 17
Florence 15
Turin 15
Zhengzhou 15
Abidjan 13
Los Angeles 12
Nanchang 11
Shanghai 11
Des Moines 10
Jiaxing 10
Pune 10
Shenyang 10
Bremen 9
Brussels 9
Bühl 8
Changsha 8
Dearborn 8
Falls Church 8
Forlì 8
Haikou 8
Medford 8
Mülheim 8
Norwalk 8
Quito 8
Guangzhou 7
Abeokuta 6
Amsterdam 6
Chicago 6
Moscow 6
Rome 6
San Giorgio di Piano 6
Skopje 6
Taizhou 6
Holon 5
Mountain View 5
Phoenix 5
Tianjin 5
Toronto 5
Verona 5
Medolla 4
Olalla 4
Philadelphia 4
Reggio Nell'emilia 4
Shenzhen 4
Taiyuan 4
Treviso 4
Wuhan 4
Bari 3
Bolzano 3
Boydton 3
Bucharest 3
Chengdu 3
Fuzhou 3
Hangzhou 3
London 3
L’Aquila 3
Mahé 3
Munich 3
Ningbo 3
Paris 3
Peshawar 3
Prineville 3
Redmond 3
Russi 3
San Lazzaro di Savena 3
Serio 3
Totale 3.476
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 204
LncRNAs as novel players in hepatocellular carcinoma recurrence 150
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 142
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 139
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 136
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 136
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 134
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 130
Oncogenic role of miR-483-3p at the IGF2/483 locus. 127
Targeting notch3 in hepatocellular carcinoma: Molecular mechanisms and therapeutic perspectives 127
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 127
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 120
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 119
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 119
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 117
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 115
GADD45alpha expression in cirrhosis and hepatocellular carcinoma. Relationship with DNA-repair and proliferation. 112
Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas 110
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 109
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 108
Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. 108
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 105
Improving accuracy in the diagnosis of small HCC (< 20 mm) on cirrhosis by a combined CT-MRI Ultrasound navigation system. Preliminary report of a work in progress. 105
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 104
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 104
MicroRNAs in Animal Models of HCC 104
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. 102
TP53/MicroRNA interplay in hepatocellular carcinoma 101
T.N.28 P53 IS REGULATED BY NOTCH3 SIGNALLING VIA MDM2 IN HEPATOCELLULAR CARCINOMA 99
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 91
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 86
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 86
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 86
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches 86
Efficacy of superselective TACE in treatment of HCC 81
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. 79
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 79
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 78
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 78
null 77
Notch3 intracellular domain accumulates in HepG2 cell line. 74
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 74
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma 70
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 69
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 64
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 48
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 47
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 46
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 44
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 42
Emerging role of microRNAs in the treatment of hepatocellular carcinoma 42
miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature 40
Animal models of hepatocellular carcinoma prevention 39
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 35
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 25
Brivanib in combination with Notch3 silencing shows potent activity in tumour models 23
Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver 23
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much s missing? 16
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 12
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC 2
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies 1
Totale 5.256
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.905
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.905
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020623 0 0 0 0 0 0 137 151 154 83 50 48
2020/2021558 109 42 16 15 11 38 43 40 75 47 24 98
2021/2022976 55 44 60 86 74 47 19 96 36 84 253 122
2022/20231.084 99 121 62 123 65 93 21 57 192 28 76 147
2023/2024411 32 70 19 37 55 79 13 20 19 30 13 24
2024/2025835 87 222 141 116 214 55 0 0 0 0 0 0
Totale 5.256